1.2023 Korean Thyroid Association Management Guidelines for Patients with Subclinical Hypothyroidism
Hyun Kyung CHUNG ; Eu Jeong KU ; Won Sang YOO ; Yea Eun KANG ; Kyeong Jin KIM ; Bo Hyun KIM ; Tae-Yong KIM ; Young Joo PARK ; Chang Ho AHN ; Jee Hee YOON ; Eun Kyung LEE ; Jong Min LEE ; Eui Dal JUNG ; Jae Hoon CHUNG ; Yun Jae CHUNG ; Won Bae KIM ; Ka Hee YI ; Ho-Cheol KANG ; Do Joon PARK
International Journal of Thyroidology 2023;16(1):32-50
Subclinical hypothyroidism (SCH), characterized by elevated serum thyroid-stimulating hormone (TSH) levels and normal free thyroxine levels, usually presents without symptoms, and is often discovered incidentally during routine blood test. The Task Force of the Korean Thyroid Association Committee of Clinical Practice Guidelines has established a guideline to evaluate and manage SCH; the guideline emphasizes the implementation of diagnostic criteria based on the TSH reference range for Koreans and focuses on the proven health benefits of levothyroxine (LT4) treatment. Based on the Korea National Health and Nutrition Examination Survey (2013-2015), serum TSH level of 6.8 mIU/L is considered the reference value for SCH. SCH can be categorized as mild (TSH 6.8-10.0 mIU/L) or severe (TSH >10.0 mIU/L), and patients are classified as adults (age <70 years) or elderly patients (age ≥70years) depending on the health effects of LT4 treatment. An initial increase in serum TSH levels should be reassessed with a subsequent measurement, along with the thyroid peroxidase antibody test, preferably 2-3 months after the initial evaluation. Usually, LT4 treatment is not recommended for mild SCH in adults; however, treatment is necessary for severe SCH in patients with underlying coronary artery disease or heart failure and can be considered for coexisting dyslipidemia. LT4 treatment is not recommended for mild or even severe SCH in elderly patients, in general. Patients with SCH who receive LT4 treatment, the LT4 dosage should be personalized, and serum TSH levels should be monitored to ensure optimal LT4 dosage (dosage that is neither excessive nor insufficient). Patients with SCH who do not receive LT4 treatment require periodic follow-up at appropriate testing intervals determined by disease severity. The guideline also provides several educational points applicable in clinical settings.
2.2023 Korean Thyroid Association Management Guidelines for Patients with Subclinical Hypothyroidism
Hyun Kyung CHUNG ; Eu Jeong KU ; Won Sang YOO ; Yea Eun KANG ; Kyeong Jin KIM ; Bo Hyun KIM ; Tae-Yong KIM ; Young Joo PARK ; Chang Ho AHN ; Jee Hee YOON ; Eun Kyung LEE ; Jong Min LEE ; Eui Dal JUNG ; Jae Hoon CHUNG ; Yun Jae CHUNG ; Won Bae KIM ; Ka Hee YI ; Ho-Cheol KANG ; Do Joon PARK
International Journal of Thyroidology 2023;16(2):214-215
3.Preoperative Videourodynamic Study Is Helpful in Predicting Long-term Postoperative Voiding Function in Asymptomatic Patients With Closed Spinal Dysraphism
Louis KIM ; Minh Tung DO ; Hyuk Dal JUNG ; Young Jae IM ; Kyu Chang WANG ; Ji Yeon LEE ; Kwanjin PARK
International Neurourology Journal 2022;26(1):60-68
Purpose:
Controversy exists regarding the role preoperative urodynamic study for asymptomatic closed spinal dysraphism as it has failed to reveal the benefit in surgical decision and expectation of urological outcomes. We explore the relationship between preoperative videourodynamic study and postoperative urological outcomes after toilet training completed, focusing on their capability of spontaneous voiding.
Methods:
We retrospectively reviewed the data of 181 patients who underwent preventive spinal cord untethering and followed at least till the completion of toilet training. Before untethering, patients underwent preoperative videourodynamic study. Postoperative voiding function was evaluated in 3 phases: (1) till postoperative 6 months, (2) till the completion of toilet training, and (3) 2 years after toilet training. Changing distribution of emptying pattern at each period was described. Also, relevance to preoperative urodynamic parameters on spontaneous voiding and urinary continence after toilet training was assessed.
Results:
Spinal lipoma and low lying conus were found in 145 (80%) and 128 patients (70.7%), respectively. Spontaneous voiding was found in 125 (69.1%), 164 (90.6%), and 162 patients (89.5%) at postoperative 6 months, till the toilet training, and 2 years after toilet training, respectively. Videourodynamics helped to clarify the presence of vesicourethral synergy. This was correlated with spontaneous voiding at postoperative 6 months and better urinary continence after 2 years of toilet training.
Conclusions
Eventual spontaneous voiding was achieved till toilet training in 90% patients following preventive untethering. Those showing preoperative vesicourethral synergy was associated with faster achievement of spontaneous voiding and better urinary continence when they enter elementary school.
4.A Position Statement of the Utilization and Support Status of Continuous Glucose Monitoring in Korea
Won Jun KIM ; Jae Hyun KIM ; Hye Jin YOO ; Jang Won SON ; Ah Reum KHANG ; Su Kyoung KWON ; Ji Hye KIM ; Tae Ho KIM ; Ohk Hyun RYU ; Kyeong Hye PARK ; Sun Ok SONG ; Kang-Woo LEE ; Woo Je LEE ; Jung Hwa JUNG ; Ho-Chan CHO ; Min Jeong GU ; Jeongrim LEE ; Dal Lae JU ; Yeon Hee LEE ; Eun Kyung KIM ; Young Sil EOM ; Sung Hoon YU ; Chong Hwa KIM ;
Journal of Korean Diabetes 2021;22(4):225-237
The accuracy and convenience of continuous glucose monitoring (CGM), which efficiently evaluates glycemic variability and hypoglycemia, are improving. There are two types of CGM: professional CGM and personal CGM. Personal CGM is subdivided into real-time CGM (rt-CGM) and intermittently scanned CGM (isCGM). CGM is being emphasized in both domestic and foreign diabetes management guidelines. Regardless of age or type of diabetes, CGM is useful for diabetic patients undergoing multiple insulin injection therapy or using an insulin pump. rt-CGM is recommended for all adults with type 1 diabetes (T1D), and can also be used in type 2 diabetes (T2D) treatments using multiple insulin injections. In some cases, short-term or intermittent use of CGM may be helpful for patients with T2D who use insulin therapy other than multiple insulin injections and/or oral hypoglycemic agents. CGM can help to achieve A1C targets in diabetes patients during pregnancy. CGM is a safe and cost-effective alternative to self-monitoring blood glucose in T1D and some T2D patients. CGM used in diabetes management works optimally with proper education, training, and follow up. To achieve the activation of CGM and its associated benefits, it is necessary to secure sufficient repetitive training and time for data analysis, management, and education. Various supports such as compensation, insurance coverage expansion, and reimbursement are required to increase the effectiveness of CGM while considering the scale of benefit recipients, policy priorities, and financial requirements.
5.Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection
Young Dal LEE ; Sung Eun KIM ; Seun Ja PARK ; Moo In PARK ; Won MOON ; Jae Hyun KIM ; Kyoungwon JUNG ; Jiyun SONG
The Korean Journal of Gastroenterology 2020;76(3):142-149
Background/Aims:
The rates of Helicobacter pylori (H. pylori) eradication have declined with the use of proton pump inhibitor-amoxicillin-clarithromycin as the first-line triple therapy. On the other hand, several studies have suggested that high gastric pH levels could affect the H. pylori eradication rate by enhancing the efficacy of antimicrobials. This study compared the efficacy of seven-day high-dose esomeprazole-based triple therapy (7-HEAC) for first-line H. pylori eradication with the seven-day standard dose non-esomeprazole-based triple therapy (7-NEAC) to identify the risk factors related to eradication failure.
Methods:
This study included 223 patients who were diagnosed with a H. pylori infection and received 7-HEAC or 7-NEAC between June 2016 and January 2017. The H. pylori eradication rates, as well as demographic and clinical factors, were investigated retrospectively. H. pylori eradication was confirmed by a 13C-urea breath test or rapid urease test at least 4 weeks after the completion of therapy.
Results:
The eradication rates were 67.7% (105/155; 95% CI 59.5-74.8%) in the 7-NEAC group and 80.9% (55/68; 95% CI 69.9-89.8%) in the 7-HEAC group (p=0.045). The adverse event rates were 5.8% (9/155) in the 7-NEAC group and 7.4% (5/68) in the 7-HEAC group (p=0.661). Multivariate analysis revealed being female (OR 2.08; 95% CI 1.15-3.76) to be associated with the failure of H. pylori eradication therapy.
Conclusions
The eradication rate of the 7-HEAC group was higher than that of the 7-NEAC group. Nevertheless, more effective first-line therapies may be necessary for H. pylori eradication in the near future.
6.Korean Mothersafe Center 10th Anniversary: Outcome and Future Prospects
Jung Yeol HAN ; Hyun Kyong AHN ; June Seek CHOI ; Gye Jeong YEOM ; So Young LEE ; Yoon Ha KIM ; Dal Soo HONG ; Seong Yeon HONG ; Jeong Sup YUN ; Hye Jin JUNG ; Hye Ji JEON ; Sung Hong JOO ; Anna CHOI ; Eui Shik JEONG
Journal of the Korean Society of Maternal and Child Health 2019;23(4):209-219
PURPOSE:
The purpose of this report is to organize the history of Korean Mothersafe, a professional teratology information center. Throughout its domestic and international activities, Mothersafe has firm role to write journals and books, to provide counseling, to run educational courses on maternal and fetal toxicology, and so on. This paper delineates the achievements in last ten years and discusses the vision of Mothersafe.
METHODS:
In order to formulate the accomplishments of Korean Mothersafe, the volume of counseling calls are carefully reviewed by their contents, counselees, and the consultation results, etc. Textbooks and journals based on the data from Mothersafe are evaluated. Other roles of the Mothersafe, such as hosting symposium and running public programs are also noted.
RESULTS:
Korean Mothersafe provided 76,555 counseling to 45,933 expectant women and 30,622 breast-feeding women. The database has total 52,130 enrollments from 2010 to 2019. A total of 33 papers are published regarding medication, alcohol, smoking, radiation, etc. A specialized book on maternal-fetal toxicology was published and teratology part of obstetrics textbook was updated. Education programs and symposiums were held and primary care programs for expectant parents are run by Mothersafe.
CONCLUSION
Korean Mothersafe has contributed to safe environments for numerous pregnant and breast-feeding women regarding medication, drinking, smoking, and other hazardous substances. The huge database provided evidence for researches, textbooks and seminars, etc. Korean Mothersafe is now facing a new challenge to go forward through social dynamics with many issues regarding prevention and continuance of pregnancy, abortion, and so on.
7.A novel RET mutation identified in a patient with pheochromocytoma and renal cell carcinoma
Jae Wan KWON ; Eui Dal JUNG ; Eon Ju JEON ; Jung Kyu PARK ; Joon Kee LEE ; Chang Ho CHO
Kosin Medical Journal 2018;33(3):446-453
Pheochromocytomas might be sporadic or genetic. Genetic pheochromocytoma is associated with multiple endocrine neoplasia (MEN) type 2A, MEN type 2B, and von Hippel-Lindau (VHL) disease. RET mutations are identified in more than 90% of index cases of MEN2 and familial medullary thyroid cancer and in about 4–12% of apparent sporadic cases. Here, we report a 54-year-old man presenting with pheochromocytoma and renal cell carcinoma, who was identified as having a novel missense RET mutation.
Carcinoma, Renal Cell
;
Humans
;
Male
;
Middle Aged
;
Multiple Endocrine Neoplasia
;
Pheochromocytoma
;
Thyroid Neoplasms
8.Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk Cohort.
Young Ah LEE ; Sun Wook CHO ; Ho Kyung SUNG ; Kyungsik KIM ; Young Shin SONG ; Sin Je MOON ; Jung Won OH ; Dal Lae JU ; Sooyeon CHOI ; Sang Hoon SONG ; Gi Jeong CHEON ; Young Joo PARK ; Choong Ho SHIN ; Sue K PARK ; Jong Kwan JUN ; June Key CHUNG
Endocrinology and Metabolism 2018;33(3):395-402
BACKGROUND: Iodine is an intrinsic element of thyroid hormone, which is essential for childhood growth and development. The Ideal Breast Milk (IBM) cohort study aims to evaluate the effects of maternal iodine status during pregnancy and lactation on maternal thyroid function, offspring growth and development, and offspring thyroid function. METHODS: The IBM cohort study recruited pregnant women from Seoul National University Hospital between June 2016 and August 2017, followed by enrollment of their offspring after delivery. For the maternal participants, iodine status is evaluated by urinary iodine concentration (UIC) and dietary records in the third trimester and at 3 to 4 weeks and 12 to 15 months postpartum. For the child participants, cord blood sampling and UIC measurements are performed at birth. At 3 to 4 weeks of age, UIC and breastmilk iodine concentrations are measured. At 12 to 15 months of age, growth and development are assessed and measurements of UIC, a thyroid function test, and ultrasonography are performed. RESULTS: A total of 198 pregnant women in their third trimester were recruited. Their mean age was 35.1±3.5 years, and 78 (39.4%) of them were pregnant with twins. Thirty-three (16.7%) of them had a previous history of thyroid disease. CONCLUSION: Korea is an iodine-replete area. In particular, lactating women in Korea are commonly exposed to excess iodine due to the traditional practice of consuming brown seaweed soup postpartum. The study of the IBM cohort is expected to contribute to developing guidelines for optimal iodine nutrition in pregnant or lactating women.
Breast*
;
Child
;
Cohort Studies*
;
Cordocentesis
;
Diet Records
;
Female
;
Growth and Development*
;
Humans
;
Infant
;
Iodine*
;
Korea
;
Lactation*
;
Milk, Human*
;
Parturition
;
Postpartum Period
;
Pregnancy Trimester, Third
;
Pregnancy*
;
Pregnant Women
;
Prospective Studies*
;
Seaweed
;
Seoul
;
Thyroid Diseases
;
Thyroid Function Tests
;
Thyroid Gland*
;
Twins
;
Ultrasonography
9.Isotretinoin exposure in pregnant women in Korea.
Nae Ry KIM ; So Ra YOON ; June Seek CHOI ; Hyun Kyong AHN ; So Young LEE ; Dal Soo HONG ; Jeong Sup YUN ; Seong Yeon HONG ; Yoon Ha KIM ; Jung Yeol HAN
Obstetrics & Gynecology Science 2018;61(6):649-654
OBJECTIVE: Isotretinoin is a notorious teratogen otherwise used for the treatment of acne vulgaris. Some countries, including those in North America and the European Union, implemented the pregnancy prevention program (PPP); however, no PPP has yet been established in South Korea. So the aim of this study was to evaluate the rate of pregnant women exposed to isotretinoin among the callers of the Korean Mother Safe Counseling Center. METHODS: This is a prospective cohort study. We evaluated the demographic characteristics, obstetric history, and isotretinoin exposure of pregnant women based on the mother safe registry from April 2010 to July 2016. RESULTS: Among 22,374 callers, 650 (2.9%) pregnant women were exposed to isotretinoin. The mean age was 29.0±4.4 years in the isotretinoin-exposed group and 32.0±4.2 years in the unexposed group (P < 0.001). Moreover, the incidence of pregnancies within 30 days after isotretinoin discontinuation or during isotretinoin intake was 78.9% (513/650). The median duration of isotretinoin exposure was 18 (1–4,231) days. Furthermore, from 2011 to 2015, the incidence of isotretinoin exposure was 2.9±1.2 pregnancies per 10,000 births in South Korea. CONCLUSION: Approximately 80% of pregnant women are exposed to isotretinoin within the recommended 30 days of contraception or during pregnancy. Therefore, the PPP has to be established in South Korea.
Acne Vulgaris
;
Cohort Studies
;
Contraception
;
Counseling
;
European Union
;
Female
;
Humans
;
Incidence
;
Isotretinoin*
;
Korea*
;
Mothers
;
North America
;
Parturition
;
Pregnancy
;
Pregnant Women*
;
Prospective Studies
10.Principles for evaluating the clinical implementation of novel digital healthcare devices
Seong Ho PARK ; Kyung Hyun DO ; Joon Il CHOI ; Jung Suk SIM ; Dal Mo YANG ; Hong EO ; Hyunsik WOO ; Jeong Min LEE ; Seung Eun JUNG ; Joo Hyeong OH
Journal of the Korean Medical Association 2018;61(12):765-775
With growing interest in novel digital healthcare devices, such as artificial intelligence (AI) software for medical diagnosis and prediction, and their potential impacts on healthcare, discussions have taken place regarding the regulatory approval, coverage, and clinical implementation of these devices. Despite their potential, ‘digital exceptionalism’ (i.e., skipping the rigorous clinical validation of such digital tools) is creating significant concerns for patients and healthcare stakeholders. This white paper presents the positions of the Korean Society of Radiology, a leader in medical imaging and digital medicine, on the clinical validation, regulatory approval, coverage decisions, and clinical implementation of novel digital healthcare devices, especially AI software for medical diagnosis and prediction, and explains the scientific principles underlying those positions. Mere regulatory approval by the Food and Drug Administration of Korea, the United States, or other countries should be distinguished from coverage decisions and widespread clinical implementation, as regulatory approval only indicates that a digital tool is allowed for use in patients, not that the device is beneficial or recommended for patient care. Coverage or widespread clinical adoption of AI software tools should require a thorough clinical validation of safety, high accuracy proven by robust external validation, documented benefits for patient outcomes, and cost-effectiveness. The Korean Society of Radiology puts patients first when considering novel digital healthcare tools, and as an impartial professional organization that follows scientific principles and evidence, strives to provide correct information to the public, make reasonable policy suggestions, and build collaborative partnerships with industry and government for the good of our patients.
Artificial Intelligence
;
Delivery of Health Care
;
Device Approval
;
Diagnosis
;
Diagnostic Imaging
;
Humans
;
Insurance Coverage
;
Korea
;
Patient Care
;
Societies
;
Software Validation
;
United States
;
United States Food and Drug Administration

Result Analysis
Print
Save
E-mail